Validation of a Novel Method to Assess the Clinical Quality of Information in Pregnancy-Related Pharmacovigilance Case Reports: A ConcePTION Project.

Détails

Ressource 1Télécharger: 38183608.pdf (750.70 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY-NC 4.0
ID Serval
serval:BIB_D5412B03225D
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Validation of a Novel Method to Assess the Clinical Quality of Information in Pregnancy-Related Pharmacovigilance Case Reports: A ConcePTION Project.
Périodique
Drug safety
Auteur⸱e⸱s
van Rijt-Weetink YRJ, Egberts TCG, van Hunsel FPAM, Lewis D.J., Yates L.M., Winterfeld U., van Puijenbroek E.P.
ISSN
1179-1942 (Electronic)
ISSN-L
0114-5916
Statut éditorial
Publié
Date de publication
03/2024
Peer-reviewed
Oui
Volume
47
Numéro
3
Pages
261-270
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
To assess the causal relationship between a medicinal product and a reported event, relevant information needs to be present. Information elements for assessing cases of exposure to medicinal products during pregnancy were predefined and used in a new tool to assess the quality of information. However, the extent in which the presence or absence of these predefined information elements is associated with the overall clinical quality of these cases, as evaluated by pharmacovigilance experts, remains uncertain.
We aimed to validate a novel method to assess the clinical quality of information in real-world pregnancy pharmacovigilance case reports.
The clinical quality of case reports regarding medicinal product exposure and pregnancy-related outcomes was appraised from spontaneous reports, literature, Teratology Information Services (UK and Switzerland), The Dutch Pregnancy Drug Register, the Gilenya pregnancy registry and the Enhanced PV programme of Novartis. Assessment was done by means of the novel standardised tool based on the presence and relevance of information, and by expert judgement. The novel tool was validated compared to the expert assessment as the gold standard expressed as the area under the receiver operating characteristic curves, after which the sensitivity and specificity were calculated using cross-tabulations. Inter-rater variability was determined by means of weighted Cohen's kappa.
One hundred and eighty-six case reports were included. The clinical quality score as assessed by the novel method was divided into three categories with cut-off values of 45% (poor to intermediate) and 65% (intermediate to excellent). Sensitivity was 0.93 and 0.96 for poor to intermediate and intermediate to excellent, respectively. Specificity was respectively 0.52 and 0.73. Inter-rater variability was 0.65 (95% confidence interval 0.53-0.78) for the newly developed approach, and 0.40 (95% confidence interval 0.28-0.52) for the gold standard assessment.
The tool described in this study using the presence and relevance of elements of information is the first designed, validated and standardised method for the assessment of the quality of information of case reports in pregnancy pharmacovigilance data. This method confers less inter-rater variability compared with a quality assessment by experts of pregnancy-related pharmacovigilance data.
Mots-clé
Humans, Pregnancy, Female, Drug-Related Side Effects and Adverse Reactions/epidemiology, Pharmacovigilance, Adverse Drug Reaction Reporting Systems, Causality, Judgment
Pubmed
Web of science
Open Access
Oui
Création de la notice
12/01/2024 12:52
Dernière modification de la notice
27/02/2024 8:30
Données d'usage